TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06209697

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: red clover
Description: Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: red clover
Description: Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
Study: NCT05861947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR106
Description: Once or twice daily
Study: NCT05536648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparing the plaque removal ability of triple head tooth brush versus single head tooth brush among school based cerebral palsy children: A Randomized Control Trial
Description: To compare the plaque removing ability of two different tooth brushes in school going cerebral palsy children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparing the plaque removal ability of triple head tooth brush versus single head tooth brush among school based cerebral palsy children: A Randomized Control Trial
Description: To compare the plaque removing ability of two different tooth brushes in school going cerebral palsy children.
Study: NCT05606146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUB SEAD
Description: The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
Study: NCT04979572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-172
Description: * Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-172
Description: * Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner
Study: NCT04870177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 infusion biweekly
Study: NCT05585372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT guided opening mobilization of cervical intervertebral foreman
Description: 1. the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~2. cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~3. Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~4. Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved.
Study: NCT05334875

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electroretinogram (ERG)
Description: Applying electrodes to assess retinal function

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual evoked potential (VEP)
Description: Applying electrodes to assess visual pathway function
Study: NCT05979662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic frontal sinus surgery grade 6(Draf III).
Description: Patients will receive endoscopic frontal sinus surgery grade 6(Draf III).
Study: NCT05448976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva and serum sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva and serum sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis.
Study: NCT05979662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic frontal sinus surgery grade 1-3(Draf I or IIa)
Description: Patients will receive endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).
Study: NCT06728761

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy urine test carried out during the intake visit on the day of the protocol
Description: Pregnancy urine test carried out during the intake visit on the day of the protocol for exclusion of pregnant woman.
Study: NCT06148285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy
Study: NCT06735040

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy
Description: Before each treatment session, the borders of the thyroid gland were marked with ultrasound by an endocrinology specialist. Eight target points (superior, mediolateral, inferior borders of the right and left thyroid lobes, right and left side of the isthmus) were demarked with a surgical pen. PMBT was applied to the marked areas on the thyroid gland, which were approximately 1 cm apart from each other.
Study: NCT04539431

Intervention type: GENETIC
Intervention: validation of new technologies
Description: Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity

Intervention type: GENETIC
Intervention: validation of new technologies
Description: Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity
Study: NCT06735040

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: In the sham PMBT group, the probe was placed similarly to the treatment group. The screen of the laser device was active; however, the energy was set to 0 J and the power to 0 Mw, and the same procedures were also performed.
Study: NCT06739434

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GCB-002
Description: GCB-002 is a self-complementary AAV9 carrying a full length human MECP2 transgenetic product.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GCB-002
Description: GCB-002 is a self-complementary AAV9 carrying a full length human MECP2 transgenetic product.
Study: NCT05810116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levagen+
Description: Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Daily dose of 1-2 capsules (1 capsule containing 350mg)
Study: NCT04202783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exosomes
Description: Focused ultrasound delivery of intravenously-infused exosomes
Study: NCT06501261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM psychotherapy
Description: psychotherapy sessions
Study: NCT05398627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amygdala Neurofeedback
Description: real-time feedback on the hemodynamic response of the amygdala during positive autobiographical memory recall
Study: NCT05829187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin
Description: dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine
Description: piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
Study: NCT06736964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Giomer
Description: based on Pre-reacted glass ionomer (PRG)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Giomer
Description: based on Pre-reacted glass ionomer (PRG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Giomer
Description: based on Pre-reacted glass ionomer (PRG)
Study: NCT06737861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buerger Exercises with Whole Body Vibration (WBV) Therapy
Description: Participants will perform Buerger exercises three times daily, with each session including three cycles. Additionally, they will receive Whole Body Vibration therapy at a frequency of 25 Hz, three times per week. Each WBV session will last 12 minutes, divided into four 3-minute bouts, aiming to improve pain, balance, and lower limb circulation in diabetic peripheral neuropathy patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buerger Exercises Only
Description: Participants will perform Buerger exercises three times daily, with each session consisting of three cycles. This exercise regimen is aimed at assessing its effectiveness on pain, balance, and circulation in diabetic peripheral neuropathy patients, serving as a comparison to the combined intervention with WBV therapy.
Study: NCT06737822

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TPF or TPX Regimen (2# ICT) --> Surgery and Adjuvant Treatment
Description: TPF:~IINJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON DAY1 ONLY INJ. 5FU 750 MG/M2 IV THROUGH INFUSION PUMP OVER 24 HOURS D 1-4~Or~TPX Regimen INJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON D1 ONLY TAB. CAPECITABINE 850-1000MG/M2 TWICE A DAY 30 MINUTES AFTER MEALS FOR 14 DAYS IN A THREE WEEKLY CYCLE~Surgery and Adjuvant Treatment Patients with PR/CR or SD will go for surgical resection. Patients having PD but still localized and resectable will be offered surgical resection, other would undergo radical CTRT or Palliative Treatment.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Surgery and Adjuvant Treatment
Description: Wide Local Excision (WLE) with Comprehensive neck dissection and Adjuvant Treatment as per current standard Guidelines.
Study: NCT06740149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells (low dose)
Description: Administered intravenously. For phase I: single infusion, 1.0×10\^6 cells/kg. For phase II: 1.0×10\^6 cells /kg once a week for a total of 4 times.
Study: NCT05829187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momordica Charantia Extract
Description: Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
Study: NCT05648656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA Nebulization
Description: Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days plus standard care of therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NS Nebulization
Description: Nebulization with 0.9% normal saline (NS) 5mL 8 hourly for 2 days plus standard care of therapy
Study: NCT06740149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells (low dose)
Description: Administered intravenously. For phase I: single infusion, 1.0×10\^6 cells/kg. For phase II: 1.0×10\^6 cells /kg once a week for a total of 4 times.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solvent of CG-BM1
Description: Administered intravenously, once a week for a total of 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells (medium dose)
Description: Administered intravenously. For phase I: single infusion, 2.0×10\^6 cells /kg. For phase II: 2.0×10\^6 cells /kg once a week for a total of 4 times.
Study: NCT04597372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.
Study: NCT06147973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Treatment (ABT)
Description: Participants will be provided with psycho-education, skill-builders, and other coaching to promote weight loss and healthy lifestyle changes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education (HE) Comparison
Description: Participants will be provided with psych-education and resources to promote weight loss and healthy lifestyle changes. They will not be provided with directives.
Study: NCT06166030

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional blend (ImmuneRecov).
Description: Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional blend (ImmuneRecov).
Description: Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.
Study: NCT06152471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC-flakes
Description: Aktive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salovum
Description: Active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drugs
Study: NCT05236127

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soccer Heading
Description: A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
Study: NCT05790304

Intervention type: DRUG
Group type: OTHER
Intervention: Camizestrant
Description: Camizestrant 75 mg tablets. Experimental drug.
Study: NCT05236127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
Study: NCT05790304

Intervention type: DRUG
Group type: OTHER
Intervention: Camizestrant
Description: Camizestrant 75 mg tablets. Experimental drug.

Intervention type: DRUG
Group type: OTHER
Intervention: Camizestrant
Description: Camizestrant 75 mg tablets. Experimental drug.
Study: NCT06071286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
Study: NCT04756895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vancomycin dose adjustment using the Bayesian method
Description: This intervention is the experimental method. The AUC/MIC target is 400-600 mg\*hour/L.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin dose adjustment using the trough level method
Description: This intervention is the standard method. Previous clinical guidelines recommended this method. The trough target is 10-15 mg/L for non-severe infections and 15-20 mg/L for severe infections.
Study: NCT06345040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual-reality intervention
Description: For the experimental condition, participants will receive seven individual sessions of Virtual Reality Therapy conducted by a therapist trained in both eating disorder psychotherapy and virtual reality-based therapy, including avatar therapy. In the initial stage of therapy participants create a virtual avatar embodying their eating disorder voice. This enables the person to engage in real time face to face dialogue with the eating disorder voice. The main goal of the intervention is to encourage participants to stand up to the negative comments and commands made by the eating disorder voice and hereby increase their power and agency in the context of the eating disorder voice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU - specialized treatment
Description: The control condition encompasses treatment as usual comprising seven sessions of specialized treatment, such as individual or group psychotherapy and dietary guidance, provided by interdisciplinary health professionals.
Study: NCT05628103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 flexibly dosed
Study: NCT06203938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial infrared light stimulation
Description: Trancranial infrared light stimulation administered via light-emitting diodes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Identical to TILS, but with lights off
Study: NCT06561490

Intervention type: RADIATION
Intervention: sonographic assesment of placental thickness and volume
Description: sonographic assesment of placental thickness and volume
Study: NCT05244980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-105795
Description: TDM-105795 topical solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for TDM-105795 topical solution
Study: NCT05547152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: massages
Description: The experimental rehabilitation protocol includes massages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massages
Description: The experimental rehabilitation protocol includes massages

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor stimulation and stretching
Description: motor stimulation and stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor stimulation and stretching
Description: motor stimulation and stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Patient watches an avatar of his face performing different movements on a screen, and will have to imagine performing these movements without actually doing them.
Study: NCT04541823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desﬂurane
Description: Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia